NASDAQ:NTNX • US67059N1081
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NUTANIX INC - A (NTNX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-26 | UBS | Maintains | Buy -> Buy |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-02-26 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-26 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-26 | B of A Securities | Maintains | Buy -> Buy |
| 2026-02-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-02-24 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2026-01-15 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2026-01-12 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2026-01-05 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-28 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-11-26 | Needham | Maintains | Buy -> Buy |
| 2025-11-26 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-11-26 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-11-26 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-11-26 | B of A Securities | Maintains | Buy -> Buy |
| 2025-11-26 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-26 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-11-26 | Northland Capital Markets | Maintains | Market Perform -> Market Perform |
| 2025-11-17 | Oppenheimer | Initiate | Outperform |
| 2025-11-17 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-28 | Needham | Maintains | Buy -> Buy |
| 2025-08-28 | Barclays | Maintains | Overweight -> Overweight |
| 2025-08-28 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.863B 17.85% | 2.149B 15.35% | 2.538B 18.11% | 2.891B 13.91% | 3.275B 13.28% | 3.69B 12.67% | 5.293B 43.44% | 6.352B 20.01% | 7.622B 19.99% | |
| EBITDA YoY % growth | -114.262M 69.18% | 97.062M 184.95% | 254.693M 162.40% | 701.95M 175.61% | 839.04M 19.53% | 971.12M 15.74% | N/A | N/A | N/A | |
| EBIT YoY % growth | -190.65M 58.43% | 23.863M 112.52% | 181.992M 662.65% | 608.95M 234.60% | 756.98M 24.31% | 910.79M 20.32% | 1.232B 35.27% | 1.681B 36.44% | 2.26B 34.44% | |
| Operating Margin | -10.23% | 1.11% | 7.17% | 21.06% | 23.11% | 24.68% | 23.28% | 26.46% | 29.65% | |
| EPS YoY % growth | 0.55 217.02% | 1.30 136.36% | 1.77 36.15% | 1.85 4.72% | 2.20 18.63% | 2.55 15.83% | N/A | N/A | N/A |
All data in USD
| Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.38 -9.61% | 0.52 41.39% | 0.51 23.44% | 0.60 6.79% | 0.52 35.71% | 0.54 3.98% | 0.60 18.24% | 0.69 15.41% | 0.63 21.43% | 0.67 23.13% |
| Revenue Q2Q % growth | 704.72M 10.29% | 763.28M 16.84% | 778.15M 16.04% | 834M 15.38% | 810.18M 14.96% | 856.58M 12.22% | 865.03M 11.16% | 907.12M 8.77% | 907.87M 12.06% | 943.7M 10.17% |
| EBITDA Q2Q % growth | 147.08M 42.66% | 194.82M 82.28% | 182.07M 151.93% | 230.21M 87.62% | 191.15M 29.96% | 209M 7.28% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 128.98M 165.15% | 180.47M 428.01% | 177.06M 228.53% | 217.27M 151.82% | 179.61M 39.25% | 192.63M 6.74% | 208.35M 17.67% | 242.73M 11.72% | 220.49M 22.76% | 238.03M 23.57% |
All data in USD
25 analysts have analysed NTNX and the average price target is 65.59 USD. This implies a price increase of 64.68% is expected in the next year compared to the current price of 39.83.
NUTANIX INC - A (NTNX) will report earnings on 2026-05-26, after the market close.
The consensus EPS estimate for the next earnings of NUTANIX INC - A (NTNX) is 0.38 USD and the consensus revenue estimate is 704.72M USD.
The number of analysts covering NUTANIX INC - A (NTNX) is 25.